News | April 30, 2008

PET Cuts Additional Procedures by 77 Percent

May 1, 2008 - The use of PET scans for cancer diagnosis, staging, restaging and recurrence monitoring was associated with a strong reduction in unnecessary additional procedures in a study by Bruce Hillner, M.D., published today in Journal of Clinical Oncology.

In the aggregate of cases with an initial treatment plan, referring physicians reported that PET scanning allowed them to avoid additional tests or procedures 77 percent of the time, the study said. Furthermore, for approximately three quarters of cases in which a biopsy was the initial pre-PET recommendation, the procedure was ultimately avoided as a result of PET scanning.

This landmark coverage with evidence development (CED) study is just the latest research to demonstrate the value of PET scanning in cancer diagnosis and treatment. For example, PET scans have also proven to produce an average savings of 13 percent through avoiding unnecessary surgery, hospital stays and intensive care. [Verboom, P et al. "Cost-Effectiveness of FDG-PET in Staging Non-Small Cell Lung Cancer: The PLUS Study." The European Journal of Nuclear Medicine and Molecular Imaging. 30.11 (2003).]

The Medical Imaging and Technology Alliance (MITA), a division of NEMA, said today that the results of the study is an important reminder of the value of medical imaging technology.

"PET scans are just one of the many medical technologies that have revolutionized the diagnosis and treatment of cancer, and this study should be strongly considered by the Centers for Medicare and Medicaid Services as it makes future National Coverage Decisions,"? said Andrew Whitman, vice president, MITA. "MITA applauds the work of Dr. Bruce Hillner and his team, which we hope will result in improved treatment and health outcomes for cancer patients with tumor types not currently on the 'approved' Medicare list. These research findings remind us that it's critical that patients have access to innovative medical imaging technology to help fight cancer and other serious illnesses."

"Now more than ever it's crucial that patients and policymakers alike look to studies like these as a reminder of why and how medical imaging improves patient health outcomes and reduces overall healthcare costs,"? Whitman said.

For more information: www.medicalimaging.org

Related Content

Bruker Introduces New High-Performance Preclinical PET/CT Si78 System
Technology | PET-CT | September 26, 2018
September 26, 2018 — Bruker recently announced the introduction of the new preclinical...
Siemens Healthineers Announces FDA Clearance of syngo.via VB30 Molecular Imaging Software
Technology | Nuclear Imaging | July 16, 2018
At the 2018 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), June 23-26 in Philadelphia...
Philips North America and GE Healthcare Win IMV PET Imaging ServiceTrak Awards
News | PET Imaging | June 25, 2018
IMV, part of the Science and Medicine Group and a market research and business intelligence provider to the imaging...
FDA Clears New Imaging Functionalities for Biograph mCT PET/CT Systems
Technology | PET-CT | June 21, 2018
Siemens Healthineers will announce U.S. Food and Drug Administration (FDA) clearance of four new system features for...
PET/CT Changes Care for 59 Percent of Suspected Recurrent Prostate Cancer Cases
News | Prostate Cancer | June 13, 2018
A recently presented investigational clinical trial evaluated the impact of 18F fluciclovine positron emission...
Nuclear imaging scan showing very good tissue delineation. Scan performed on a Biograph Vision positron emission tomography/computed tomography (PET-CT) system from Siemens Healthineers.

Nuclear imaging scan showing very good tissue delineation. It offers crisp overall image quality and sharply delineates the muscle and fat planes, vertebral margins and end plates, billiary radicals, renal calyces, aortic wall and papillary muscles of the heart. Scan performed on a Biograph Vision positron emission tomography/computed tomography (PET-CT) system from Siemens Healthineers.

Technology | PET-CT | June 05, 2018
June 5, 2018 — The U.S.
News | Computed Tomography (CT) | May 21, 2018
The Istituto Oncologico Veneto (IOV) in Padua, Italy, has acquired MILabs’ latest-generation Versatile Emission...
News | Radiopharmaceuticals and Tracers | May 09, 2018
Blue Earth Diagnostics signed an exclusive, worldwide agreement with Scintomics GmbH, Germany, a specialist in...
In scans of a 62-yr-old man with Gleason 4+3 PCa treated with radical prostatectomy, with rising PSA level (1.32) and PSA doubling time of 3.7 months, 64CuCl2-PET/CT images revealed 2 positive small left iliac lymph nodes (A,C), whereas 18F-Choline PET/CT (B,D) was negative (arrows).

In scans of a 62-yr-old man with Gleason 4+3 PCa treated with radical prostatectomy, with rising PSA level (1.32) and PSA doubling time of 3.7 months, 64CuCl2-PET/CT images revealed 2 positive small left iliac lymph nodes (A,C), whereas 18F-Choline PET/CT (B,D) was negative (arrows). Image courtesy of A Piccardo et al., Galliera Hospital, Genoa, Italy.

News | Prostate Cancer | March 07, 2018
An Italian study featured in the March i
Axumin PET Agent Added to NCCN Guidelines for Suspected Recurrent Prostate Cancer
News | PET Imaging | February 21, 2018
Blue Earth Diagnostics announced that Axumin (fluciclovine F 18) injection has been added to the National Comprehensive...